Literature DB >> 23659763

Overexpression of PLCE1 in Kazakh esophageal squamous cell carcinoma: implications in cancer metastasis and aggressiveness.

Yun-Zhao Chen1, Xiao-Bin Cui, Jian-Ming Hu, Wen Jie Zhang, Shu-Gang Li, Lan Yang, Xi-Hua Shen, Chun-Xia Liu, Qing-Fang Pan, Shi-Ying Yu, Xiang-Lin Yuan, Lei Yang, Wen-Yi Gu, Jie-Zhong Chen, Li-Dong Wang, Feng Li.   

Abstract

Three recent large-scale genome-wide association studies (GWAS) in Chinese Han populations have identified an esophageal squamous cell carcinoma (ESCC) susceptibility locus within phospholipase C epsilon 1 (PLCE1) gene, which encodes a phospholipase involved in intracellular signaling. The expressed PLCE1 in ESCC, however, are inconsistent. This study examined PLCE1 expression by immunohistochemistry (IHC) from 110 ethnic Kazakh ESCC patients and 50 from adjacent normal esophageal tissues (NETs). The expressed PLCE1 was localized in cytoplasm, especially in the peripheral layers of cancer cell nests, which was significantly higher in tumors than in NETs (p < 0.001). Increased expression of PLCE1 was correlated with advanced tumor-node-metastasis (TNM) stages (p = 0.015) and lymph node metastasis (p = 0.003) in patients with ESCC. Of the 110 patients, we examined 50 paired ESCC tissues and corresponding NETs by quantitative RT-PCR (polymerase chain reaction) and the mean mRNA level of PLCE1 in ESCC was 1.85-fold higher compared with those in corresponding NETs (p = 0.0012). Meanwhile, 4 of 5 ESCC cell lines also showed elevated expression of PLCE1 mRNA. Furthermore, elevated expression of PLCE1 mRNA in Kazakh ESCC was associated with its immunoreactivity (ρ = 0.297, p = 0.040), lymph node metastasis (p < 0.001), and advanced TNM stages of ESCC (p = 0.013). To our knowledge, this study demonstrates for the first time that PLCE1 overexpression correlates with lymph node metastasis and advanced TNM stages of Kazakh ESCC, implicating a role of PLCE1 in cancer metastasis and aggressiveness in ethnic Kazakh patients with ESCC. Furthermore, the current findings may warrant investigations into whether inhibiting PLCE1 could be a strategy for targeted anticancer therapy particularly for Kazakh ESCC.
© 2013 APMIS Published by Blackwell Publishing Ltd.

Entities:  

Keywords:  Kazakh esophageal squamous cell carcinoma; aggressiveness; cancer metastasis; phospholipase C epsilon 1 (PLCE1)

Mesh:

Substances:

Year:  2013        PMID: 23659763     DOI: 10.1111/apm.12095

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  21 in total

1.  RANK overexpression as a novel esophageal cancer marker: validated immunohistochemical analysis of two different ethnicities.

Authors:  Xiaobin Cui; Hao Peng; Jing Jin; Tingting Li; Shumao Zhang; Tingting Jin; Su Li; Chunxia Liu; Weihua Liang; Feng Li; Yunzhao Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  CYP1A1 and CYP2E1 genotypes and risk of esophageal squamous cell carcinoma in a high-incidence region, Kashmir.

Authors:  Gulzar Ahmad Bhat; Idrees Ayoub Shah; Muzamil Ashraf Makhdoomi; Beenish Iqbal; Rumaisa Rafiq; Sumaiya Nabi; Akbar Masood; Mohd Maqbool Lone; Nazir Ahmad Dar
Journal:  Tumour Biol       Date:  2014-02-08

3.  Tumor necrosis factor-α gene 308G/A polymorphism is not associated with esophageal squamous cell carcinoma risk in Kazakh patients.

Authors:  Xiao-Bin Cui; Dan-Dan Wang; Hai-Yang Zhang; Ting-Ting Li; Ting-Ting Jin; Hao Peng; Shu-Mao Zhang; Bin Wang; Jie Yu; Chun-Xia Liu; Lan Yang; Jing Jin; Su Li; Jin-Fang Jiang; Wei-Hua Liang; Jian-Ming Hu; Shu-Gang Li; Chuan-Yue Wu; Yun-Zhao Chen; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  PLCE1 mRNA and protein expression and survival of patients with esophageal squamous cell carcinoma and gastric adenocarcinoma.

Authors:  Wen-Qing Li; Nan Hu; Victoria H Burton; Howard H Yang; Hua Su; Catherine M Conway; Lemin Wang; Chaoyu Wang; Ti Ding; Yi Xu; Carol Giffen; Christian C Abnet; Alisa M Goldstein; Stephen M Hewitt; Philip R Taylor
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-27       Impact factor: 4.254

5.  A multigenic approach to evaluate genetic variants of PLCE1, LXRs, MMPs, TIMP, and CYP genes in gallbladder cancer predisposition.

Authors:  Kiran Lata Sharma; Rajani Rai; Anshika Srivastava; Aarti Sharma; Sanjeev Misra; Ashok Kumar; Balraj Mittal
Journal:  Tumour Biol       Date:  2014-05-27

6.  Comprehensive bioinformation analysis of the miRNA of PLCE1 knockdown in esophageal squamous cell carcinoma.

Authors:  Xiaobin Cui; Kaige Wang; Xinqian Yang; Hao Peng; Xi Chen; Huahua Xin; Yanxia Tian; Yunzhao Chen; Feng Li
Journal:  Mol Cell Biochem       Date:  2017-12-13       Impact factor: 3.396

7.  Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma.

Authors:  Xiaobin Cui; Su Li; Tingting Li; Xuelian Pang; Shumao Zhang; Jing Jin; Jianming Hu; Chunxia Liu; Lan Yang; Hao Peng; Jinfang Jiang; Weihua Liang; Jing Suo; Feng Li; Yunzhao Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

8.  Phospholipase C ε-1 gene polymorphisms and prognosis of esophageal cancer patients from a high-incidence region in northern China.

Authors:  Rong-Miao Zhou; Yan Li; Na Wang; Xi Huang; Shi-Ru Cao
Journal:  Mol Clin Oncol       Date:  2017-10-27

9.  Elevated expression patterns and tight correlation of the PLCE1 and NF-κB signaling in Kazakh patients with esophageal carcinoma.

Authors:  Xiao-Bin Cui; Xue-Lian Pang; Su Li; Jing Jin; Jian-Ming Hu; Lan Yang; Chun-Xia Liu; Li Li; Shu Jun Wen; Wei-Hua Liang; Yun-Zhao Chen; Feng Li
Journal:  Med Oncol       Date:  2013-12-05       Impact factor: 3.064

10.  SLC39A6: a potential target for diagnosis and therapy of esophageal carcinoma.

Authors:  Xiao-Bin Cui; Yao-Yuan Shen; Ting-Ting Jin; Su Li; Ting-Ting Li; Shu-Mao Zhang; Hao Peng; Chun-Xia Liu; Shu-Gang Li; Lan Yang; Na Li; Jian-Ming Hu; Jin-Fang Jiang; Man Li; Wei-Hua Liang; Yong Li; Yu-Tao Wei; Zhen-Zhu Sun; Chuan-Yue Wu; Yun-Zhao Chen; Feng Li
Journal:  J Transl Med       Date:  2015-10-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.